Aptevo Therapeutics (NASDAQ:APVO) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVOFree Report) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Trading Down 5.5 %

Shares of NASDAQ:APVO opened at $0.73 on Thursday. Aptevo Therapeutics has a one year low of $0.70 and a one year high of $91.96. The company has a 50 day moving average of $4.67 and a 200-day moving average of $7.65.

Institutional Investors Weigh In On Aptevo Therapeutics

Several institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in Aptevo Therapeutics during the first quarter valued at approximately $152,000. Vanguard Group Inc. grew its holdings in Aptevo Therapeutics by 7.3% during the first quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 16,337 shares during the period. Renaissance Technologies LLC grew its holdings in Aptevo Therapeutics by 18.7% during the second quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 11,000 shares during the period. Virtu Financial LLC acquired a new position in Aptevo Therapeutics during the second quarter valued at approximately $46,000. Finally, Citadel Advisors LLC acquired a new position in Aptevo Therapeutics during the third quarter valued at approximately $51,000. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Read More

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.